A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

Lenacapavir, which was approved by the United States' Food and Drug Administration in June this year, is taken twice per year ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...